Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 104Lung Neoplasms 44Breast Neoplasms 41Triple Negative Breast Neoplasms 33Ovarian Neoplasms 29Small Cell Lung Carcinoma 25Squamous Cell Carcinoma of Head and Neck 24Fallopian Tube Neoplasms 18Neoplasms 17Endometrial Neoplasms 17Uterine Cervical Neoplasms 13Neoplasm Metastasis 13Head and Neck Neoplasms 13Esophageal Squamous Cell Carcinoma 12Prostatic Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 10Esophageal Neoplasms 10Colorectal Neoplasms 10Carcinoma, Squamous Cell 9Recurrence 8Carcinoma, Transitional Cell 8Oropharyngeal Neoplasms 7Neuroblastoma 6Carcinoma, Ovarian Epithelial 6Urinary Bladder Neoplasms 5Mesothelioma 5Lymphoma, Large B-Cell, Diffuse 5Adenocarcinoma of Lung 5Stomach Neoplasms 4Pathologic Complete Response 4

Interventions

Radiotherapy 2tislelizumab 1pembrolizumab 1TP protocol 1Paclitaxel 1Lomustine 1Cisplatin 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Recurrence, Local × Carboplatin × Clear all
NCT06942416 2025-04-24

Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
36 enrolled
Gynecologic

Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡